AA
MLTX icon

ALPS Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

ALPS Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58,395
Closed -$1.09M – 1200
2026
Q1 		$1.09M Buy
58,395
+226
+0.4% +$3.74K 0.01% 575
2025
Q4 		$767K Buy
58,169
+27,413
+89% +$323K ﹤0.01% 636
2025
Q3 		$221K Sell
30,756
-3,534
-10% -$184K ﹤0.01% 1005
2025
Q2 		$1.62M Sell
34,290
-12,811
-27% -$522K 0.01% 396
2025
Q1 		$1.84M Sell
47,101
-3,894
-8% -$168K 0.01% 360
2024
Q4 		$2.76M Buy
50,995
+7,167
+16% +$366K 0.02% 302
2024
Q3 		$2.21M Sell
43,828
-5,214
-11% -$244K 0.01% 341
2024
Q2 		$2.16M Buy
49,042
+6,769
+16% +$287K 0.01% 326
2024
Q1 		$2.12M Buy
42,273
+3,376
+9% +$183K 0.02% 340
2023
Q4 		$2.35M Buy
+38,897
New +$2M 0.02% 312
2022
Q4 		– Sell
-20,144
Closed -$160K – 1069
2022
Q3 		$160K Sell
20,144
-11,116
-36% -$78.6K ﹤0.01% 1017
2022
Q2 		$164K Buy
+31,260
New +$196K ﹤0.01% 1004

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ALPS Advisors's MLTX Position: Q2 2026 in Review

ALPS Advisors sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2026, closing a stake of 58,395 shares — an estimated $1.09M sold.

ALPS Advisors first reported a position in MLTX in Q2 2022 and held it in 12 quarters. The position peaked at $2.76M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • ALPS Advisors reported no remaining MoonLake Immunotherapeutics position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 58,395 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.09M.
  • ALPS Advisors first reported a position in MoonLake Immunotherapeutics in Q2 2022 and held it in 12 quarters.
  • ALPS Advisors's MoonLake Immunotherapeutics position peaked at $2.76M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.